AlphAIAlphAI — Financial news for AI agents
nbcnewyork.com$NVS

The ‘slam dunk’ that wasn’t: Promising cholesterol drug fails to prevent heart attacks or stroke

Novartis' experimental drug pelacarsen failed to reduce heart attacks or strokes in a clinical trial, despite lowering lipoprotein(a) levels by 78%. The Horizon trial, led by Dr. Steven Nissen, included 8,322 participants with high Lp(a) levels. Experts express surprise and disappointment, but note Lp(a) remains a key heart health indicator. Other drugs by Eli Lilly, Amgen, and Silence Therapeutics are in development.

Original reporting
nbcnewyork.com
Published Nov 7, 2026, 3:38 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 7, 2026, 5:15 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefFinancial news
Primary signal
$NVS
Bearish
high confidence
Mentioned
$NVS
Relevance
7/10
AlphAI data visualization · based on nbcnewyork.com
Decision brief

The 30-second read

$NVSBearishMed
01

Why it matters

The negative result challenges the hypothesis that Lp(a) reduction alone improves outcomes, potentially dampening investor enthusiasm for similar approaches.

02

Market read

The trial outcome is a primary biotech news event that can move Novartis and influence sentiment toward the broader Lp(a) therapeutic space.

03

What to watch

The drug achieved a 78% Lp(a) reduction, indicating strong target engagement that could be leveraged in future combinations.

Relevance 7/10Novelty 8/10Timing: today

Background

Novartis presented Horizon trial data at the American Heart Association meeting, showing no cardiovascular outcome benefit despite large Lp(a) lowering.

Company-level read

Ticker impact

$NVSBearishHigh confidence
Context

Novartis' experimental cholesterol drug pelacarsen failed to show any reduction in heart attacks or stroke in the Horizon trial.

Expected impact

downward pressure as the market prices in the lack of efficacy

Evidence & confidence

A large‑cap biotech with a high‑profile trial that delivered no cardiovascular benefit signals a setback for the pipeline and may trigger a sell‑off.

Market effects

Sector

Lipid‑lowering and cardiovascular drug sector may see heightened scrutiny of similar antisense and siRNA programs.

Regional

US biotech sector could experience short‑term weakness.

Global

Global investors in cardiovascular therapeutics may reassess pipelines and funding.

Counterpoint

What could challenge this read

Some analysts may argue the Lp(a) reduction still offers long‑term value and the trial design limited the observed benefit.

Key entities

  • Company
    Novartis

    Developer of pelacarsen, a lipid‑lowering antisense drug.

  • Company
    Eli Lilly

    Developer of a competing Lp(a) siRNA candidate.

  • Company
    Amgen

    Developer of another Lp(a) siRNA candidate.

Read at source← All news

StoryNovartis halts pelacarsen after Phase III trial shows no cardiovascular benefit

Related articles

$NVSHigh

Novartis shelves potential blockbuster pelacarsen as landmark study fails

Novartis AG is halting development of pelacarsen, an experimental cardiovascular drug, after a key study showed it failed to reduce heart attacks or strokes despite lowering cholesterol. The company will continue one mid-stage study for a different heart condition. The Lp(a) HORIZON trial, published in the New England Journal of Medicine, found no clinical benefit from the drug. According to Dr. Steven Nissen, the trial results were neutral, offering no harm or benefit.

investing.com
$NVSLow

Failure of Novartis Lp(a) drug raises questions about cardiovascular strategy

Novartis's experimental drug pelacarsen, which targets lipoprotein(a) (Lp(a)), a genetic cardiovascular risk factor, failed to reduce serious outcomes in a Phase 3 trial. The study, revealed at the American Heart Association's scientific sessions, showed the drug lowered Lp(a) levels but did not decrease heart attacks, strokes, or deaths over nearly five years. This raises questions about Novartis's cardiovascular strategy.

statnews.com
$NVSMed

Cholesterol drug pelacarsen fails to prevent heart attacks in major trial

Novartis' experimental cholesterol drug pelacarsen failed to reduce heart attacks or strokes in a major clinical trial, despite significantly lowering lipoprotein(a) levels. The Horizon trial, led by Dr. Steven Nissen, included 8,322 patients and found no cardiovascular health benefits. Experts express surprise and discuss potential reasons for the failure, while noting ongoing research into similar drugs by Eli Lilly, Amgen, and Silence Therapeutics.

nbcnews.com